{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:44:07Z","timestamp":1780616647339,"version":"3.54.1"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T00:00:00Z","timestamp":1614816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> Relapsed hepatoblastoma (HBL) and upfront hepatocellular carcinoma (HCC) are notoriously chemoresistant tumors associated with poor outcomes. Gankyrin (Gank) is a known oncogene that is overexpressed in pediatric liver cancer and implicated in chemo-resistance. The goal of this study was to evaluate if the Gank-tumor suppressor axis is activated in chemoresistant hepatoblastoma patients and examine if an inhibitor of Gank, Cjoc42, might improve the chemosensitivity of cancer cells.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> Expression of Gank and its downstream targets were examined in fresh human HBL samples using immunostaining, QRT-PCR, and Western Blot. Cancer cells, Huh6 (human HBL) and Hepa1c1c7 (mouse HCC) were treated with Cjoc42 and with Cjoc42 in combination with cisplatin or doxorubicin. Cell proliferation, apoptosis, and chemoresistance were examined. To examine activities of Cjoc42 <jats:italic>in vivo<\/jats:italic>, mice were treated with different doses of Cjoc42, and biological activities of Gank and cytotoxicity of Cjoc42 were tested.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Elevation of Gank and Gank-mediated elimination of TSPs are observed in patients with minimal necrosis after chemotherapy and relapsed disease. The treatment of Huh6 and Hepa1c1c7 with Cjoc42 was not cytotoxic; however, in combination with cisplatin or doxorubicin, Cjoc42 caused a significant increase in cytotoxicity compared to chemotherapy alone with increased apoptosis. Examination of Cjoc42 in WT mice showed that Cjoc42 is well tolerated without systemic toxicity, and levels of tumor suppressors CUGBP1, Rb, p53, C\/EBP\u03b1, and HNF4\u03b1 are increased by blocking their Gank-dependent degradation.<\/jats:p><jats:p><jats:bold>Conclusions:<\/jats:bold> Our work shows that Cjoc42 might be a promising adjunct to chemotherapy for the treatment of severe pediatric liver cancer and presents mechanisms by which Cjoc42 increases chemo-sensitivity.<\/jats:p>","DOI":"10.3389\/fphar.2021.580722","type":"journal-article","created":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T07:03:55Z","timestamp":1614841435000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Small Molecule Cjoc42 Improves Chemo-Sensitivity and Increases Levels of Tumor Suppressor Proteins in Hepatoblastoma Cells and in Mice by Inhibiting Oncogene Gankyrin"],"prefix":"10.3389","volume":"12","author":[{"given":"Amber M.","family":"D\u2019Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Cast","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meenasri","family":"Kumbaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruhi","family":"Gulati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Smithrud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Geller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Timchenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1053\/j.sempedsurg.2016.09.002","article-title":"Malignant tumors of the liver in children","volume":"25","author":"Aronson","year":"2016","journal-title":"Semin. Pediatr. Surg."},{"key":"B2","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/s0065-230x(03)88305-7","article-title":"Aberrant ubiquitin-mediated proteolysis of cell cycle regulatory proteins and oncogenesis","volume":"88","author":"Bashir","year":"2003","journal-title":"Adv. Cancer Res."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1002\/hep.29677","article-title":"C\/EBP\u03b1-dependent preneoplastic tumor foci are the origin of hepatocellular carcinoma and aggressive pediatric liver cancer","volume":"67","author":"Cast","year":"2018","journal-title":"Hepatology"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/hep4.1381","article-title":"Liver proliferation is an essential driver of fibrosis in mouse models of nonalcoholic fatty liver disease","volume":"3","author":"Cast","year":"2019","journal-title":"Hepatol. Commun."},{"key":"B5","doi-asserted-by":"publisher","first-page":"23732","DOI":"10.1038\/srep23732","article-title":"Discovery of a small-molecule binder of the oncoprotein gankyrin that modulates gankyrin activity in the cell","volume":"6","author":"Chattopadhyay","year":"2016","journal-title":"Sci. Rep."},{"key":"B6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.12688\/f1000research.12239.1","article-title":"Hepatoblastoma: current understanding, recent advances, and controversies","volume":"7","author":"Czauderna","year":"2018","journal-title":"F1000Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.jcmgh.2018.05.007","article-title":"Gankyrin promotes tumor-suppressor protein degradation to drive hepatocyte proliferation","volume":"6","author":"D\u2019Souza","year":"2018","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.bbadis.2008.08.003","article-title":"Hepatocellular carcinoma and the ubiquitin-proteasome system","volume":"1782","author":"Dawson","year":"2008","journal-title":"Biochim. Biophys. Acta"},{"key":"B9","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B10","doi-asserted-by":"publisher","first-page":"81156","DOI":"10.18632\/oncotarget.13215","article-title":"Gankyrin sustains PI3K\/GSK-3\u03b2\/\u03b2-catenin signal activation and promotes colorectal cancer aggressiveness and progression","volume":"7","author":"He","year":"2016","journal-title":"Oncotarget"},{"key":"B11","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/71600","article-title":"Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas","volume":"6","author":"Higashitsuji","year":"2000","journal-title":"Nat. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"293","DOI":"10.3978\/j.issn.2224-4336.2014.09.01","article-title":"Pediatric hepatoblastoma: diagnosis and treatment","volume":"3","author":"Hiyama","year":"2014","journal-title":"Transl Pediatr."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.bbrc.2017.06.164","article-title":"Inducible liver-specific overexpression of gankyrin in zebrafish results in spontaneous intrahepatic cholangiocarcinoma and hepatocellular carcinoma formation","volume":"490","author":"Huang","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1002\/hep.26146","article-title":"Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer","volume":"57","author":"Jiang","year":"2013","journal-title":"Hepatology"},{"key":"B15","doi-asserted-by":"publisher","first-page":"126889","DOI":"10.1016\/j.bmcl.2019.126889","article-title":"Structural modification of the aryl sulfonate ester of Cjoc42 for enhanced gankyrin binding and anti-cancer activity","volume":"30","author":"Kanabar","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1128\/MCB.00128-17","article-title":"RNA binding protein CUGBP1 inhibits liver cancer in a phosphorylation-dependent manner","volume":"37","author":"Lewis","year":"2017","journal-title":"Mol. Cel. Biol"},{"key":"B17","first-page":"1949","article-title":"Gankyrin as a potential target for tumor therapy: evidence and perspectives","volume":"10","author":"Li","year":"2018","journal-title":"Am. J. Transl Res."},{"key":"B18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.canlet.2018.11.030","article-title":"Gankyrin drives metabolic reprogramming to promote tumorigenesis, metastasis and drug resistance through activating \u03b2-catenin\/c-Myc signaling in human hepatocellular carcinoma","volume":"443","author":"Liu","year":"2019","journal-title":"Cancer Lett."},{"key":"B19","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41467-018-03106-1","article-title":"Systematic analysis of protein turnover in primary cells","volume":"9","author":"Mathieson","year":"2018","journal-title":"Nat. Commun."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1016\/j.celrep.2018.07.014","article-title":"Elimination of age-associated hepatic steatosis and correction of aging phenotype by inhibition of cdk4-C\/EBP\u03b1-p300 axis","volume":"24","author":"Nguyen","year":"2018","journal-title":"Cell Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1053\/j.gastro.2012.02.042","article-title":"p28(GANK) prevents degradation of Oct4 and promotes expansion of tumor-initiating cells in hepatocarcinogenesis","volume":"142","author":"Qian","year":"2012","journal-title":"Gastroenterology"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1111\/cas.13341","article-title":"Gankyrin induces STAT3 activation in tumor microenvironment and sorafenib resistance in hepatocellular carcinoma","volume":"108","author":"Sakurai","year":"2017","journal-title":"Cancer Sci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/1476-4598-12-114","article-title":"LBH589 Inhibits proliferation and metastasis of hepatocellular carcinoma via inhibition of gankyrin\/STAT3\/Akt pathway","volume":"12","author":"Song","year":"2013","journal-title":"Mol. Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3389\/fphar.2018.00268","article-title":"Arctigenin inhibits liver cancer tumorigenesis by inhibiting gankyrin expression via C\/EBP\u03b1 and PPAR\u03b1","volume":"9","author":"Sun","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.17140\/CSMMOJ-1-104","article-title":"Elimination of tumor suppressor proteins during liver carcinogenesis","volume":"1","author":"Timchenko","year":"2015","journal-title":"Cancer Stud. Mol. Med.\u2014Open J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1093\/carcin\/bgx050","article-title":"FXR-Gankyrin axis is involved in development of pediatric liver cancer","volume":"38","author":"Valanejad","year":"2017","journal-title":"Carcinogenesis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s42003-018-0077-8","article-title":"PARP1 activation increases expression of modified tumor suppressors and pathways underlying development of aggressive hepatoblastoma","volume":"1","author":"Valanejad","year":"2018","journal-title":"Commun. Biol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1172\/JCI41933","article-title":"Elimination of C\/EBPalpha through the ubiquitin-proteasome system promotes the development of liver cancer in mice","volume":"120","author":"Wang","year":"2010","journal-title":"J. Clin. Invest."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21691401.2017.1388250","article-title":"Gankyrin: a novel promising therapeutic target for hepatocellular carcinoma","volume":"46","author":"Zamani","year":"20178","journal-title":"Artif. Cell Nanomed. Biotechnol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.580722\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,4]],"date-time":"2021-03-04T07:03:59Z","timestamp":1614841439000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.580722\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,4]]},"references-count":29,"alternative-id":["10.3389\/fphar.2021.580722"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.580722","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,4]]},"article-number":"580722"}}